Date: 2012-07-23
Type of information: Product acquisition
Compound: FX125L compound and somatotaxin programm
Company: Boehringer Ingelheim (Germany) Funxional Therapeutics (UK)
Therapeutic area: Inflammatory diseases
Type agreement: product acquisition
Action mechanism: The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by Funxional Therapeutics. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. Funxional Therapeutics\'s portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery. The lead product (FX125L, an orally available, once-daily small molecule) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases.
Disease: inflammation, inflammatory diseases
Details: Boehringer Ingelheim and Funxional Therapeutics, a clinical-stage, asset-centric, private company, have announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L.
Financial terms: Financial details of the transaction were not disclosed.
Latest news:
